Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NCF1 | P14598 | 1/20 | 0.50 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.48 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.48 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.46 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GPR3 | P46089 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30824524 | 1.00 | NCF1 (0.50) | NCF1MAP3K5PCSK9NUDT1FDPS | |
| SCHEMBL13222944 | 0.85 | MAP3K5 (0.38) | NCF1MAP3K5PCSK9NUDT1FDPS | |
| SCHEMBL6467426 | 0.83 | MAP3K5 (0.54) | NCF1MAP3K5PCSK9FDPSEGFR | |
| SCHEMBL28028429 | 0.79 | FDPS (0.44) | NCF1MAP3K5PCSK9FDPSEGFR | |
| SCHEMBL28184943 | 0.79 | FDPS (0.48) | NCF1MAP3K5PCSK9FDPSEGFR | |
| SCHEMBL2338189 | 0.79 | MAPT (0.46) | NCF1MAP3K5PCSK9FDPSEGFR | |
| SCHEMBL4587589 | 0.79 | FDPS (0.44) | NCF1MAP3K5PCSK9FDPSEGFR | |
| SCHEMBL41211 | 0.79 | PCSK9 (0.48) | NCF1MAP3K5PCSK9FDPSEGFR | |
| SCHEMBL30961064 | 0.79 | MAPT (0.46) | NCF1MAP3K5PCSK9FDPSEGFR | |
| SCHEMBL18232970 | 0.79 | ATM (0.46) | MAP3K5PCSK9FDPSEGFRCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023138412-A1 | FUSED PYRIMIDIN-2-AMINE COMPOUNDS AS CDK20 INHIBITORS | INSILICO MEDICINE IP LIMITED (CN) | 2023-07-27 | — | — | WO | disclosed |
| EP-3246963-B1 | ORGANIC LIGHT-EMITTING DEVICE | SAMSUNG DISPLAY CO LTD (KR) | 2023-05-31 | — | — | EP | disclosed |
| US-11319303-B2 | Compound used as autophagy regulator, and preparation method therefor and uses thereof | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2022-05-03 | — | — | US | disclosed |
| EP-3301097-B1 | [1]BENZOTHIENO[3',2':4,5]IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN ORGANIC LIGHT-EMITTING DEVICES (OLEDS) | SAMSUNG DISPLAY CO LTD (KR) | 2020-08-19 | — | — | EP | disclosed |
| EP-3693372-A1 | BENZOFURO[3',2':4,5]IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN ORGANIC LIGHT-EMITTING DEVICES (OLEDS) | Samsung Display Co., Ltd. (KR) | 2020-08-12 | — | — | EP | disclosed |
| US-20200190066-A1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2020-06-18 | — | — | US | disclosed |
| US-20200069609-A1 | METHOD FOR COVALENT BOND MODIFYING MAMMALIAN ATG8 HOMOLOGUE | Wigen Biomedicine Technology (shanghai) Co., Ltd. (CN) | 2020-03-05 | — | — | US | disclosed |
| EP-3301097-A2 | [1]BENZOTHIENO[3',2':4,5]IMIDAZO[1,2-A]PYRIDINE DERIVATIVES AND RELATED COMPOUNDS FOR USE IN ORGANIC LIGHT-EMITTING DEVICES (OLEDS) | Samsung Display Co., Ltd. (KR) | 2018-04-04 | — | — | EP | disclosed |
| WO-2017046739-A1 | IMIDAZOLIDINONE DERIVATIVES AS INHIBITORS OF PERK | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-03-23 | — | — | WO | disclosed |
| US-20160332996-A1 | Hepatitis B Antiviral Agents | ENANTA PHARMACEUTICALS, INC. | 2016-11-17 | — | — | US | disclosed |
| US-9174992-B2 | Heterobicyclic compounds | AMGEN INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-9108963-B2 | Pyrazolopyridine, pyrazolopyrazine, pyrazolopyrimidine, pyrazolothiophene and pyrazolothiazole compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2015-08-18 | — | — | US | disclosed |
| WO-2013130890-A1 | HETEROBICYCLIC COMPOUNDS AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | AMGEN INC. (US) | 2013-09-06 | — | — | WO | disclosed |
| US-20130225552-A1 | HETEROBICYCLIC COMPOUNDS | AMGEN INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-8440674-B2 | Substituted pyrimidine compounds as RAF inhibitors and methods of use | AMGEN INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20130065895-A1 | Pyrazolopyridine, Pyrazolopyrazine, Pyrazolopyrimidine, Pyrazolothiophene and Pyrazolothiazole Compounds as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction | VANDERBILT UNIVERSITY (US) | 2013-03-14 | — | — | US | disclosed |
| US-20110251199-A1 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-7989461-B2 | Substituted quinazolinamine compounds for the treatment of cancer | AMGEN INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251199-A1 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS AND METHODS OF USE | BRAF, RAF1, NRAS | NCF1 247/4885MAP3K5 30/4885PCSK9 3869/4885 |
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | BRAF, NRAS, RAF1 | NCF1 241/4885MAP3K5 35/4885PCSK9 3667/4885 |
| US-20130065895-A1 | Pyrazolopyridine, Pyrazolopyrazine, Pyrazolopyrimidine, Pyrazolothiophene and Pyrazolothiazole Compounds as MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction | GRM4, GRIK4, GRIA4 | NCF1 3467/4885MAP3K5 802/4885PCSK9 4575/4885 |
| US-11319303-B2 | Compound used as autophagy regulator, and preparation method therefor and uses thereof | ATG7, SQSTM1, BECN1 | NCF1 1798/4885MAP3K5 1541/4885PCSK9 3659/4885 |
| US-20130225552-A1 | HETEROBICYCLIC COMPOUNDS | PDE10A, PDE1B, PDE9A | NCF1 3285/4885MAP3K5 2071/4885PCSK9 279/4885 |
| US-20200069609-A1 | METHOD FOR COVALENT BOND MODIFYING MAMMALIAN ATG8 HOMOLOGUE | ATG7, ATG4A, MLST8 | NCF1 2902/4885MAP3K5 2514/4885PCSK9 4751/4885 |
| US-20200190066-A1 | COMPOUND USED AS AUTOPHAGY REGULATOR, AND PREPARATION METHOD THEREFOR AND USES THEREOF | ATG7, SQSTM1, BECN1 | NCF1 1798/4885MAP3K5 1541/4885PCSK9 3659/4885 |
| US-20160332996-A1 | Hepatitis B Antiviral Agents | ZC3HAV1, ZC3HAV1L, HAVCR2 | NCF1 1091/4885MAP3K5 3734/4885PCSK9 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.